R. Shabrawy, Mariam A Maged, Nehal A Mahmoud, Nehal M ElShabrawy
{"title":"T cell Immune Pathways Current and Future Implementation in Cancer Immunotherapy","authors":"R. Shabrawy, Mariam A Maged, Nehal A Mahmoud, Nehal M ElShabrawy","doi":"10.31031/nacs.2019.03.000570","DOIUrl":null,"url":null,"abstract":"Tumor immunotherapy exceeds radiotherapy and chemotherapy in the fact that it considered the most tumor-specific therapy; it is characteristically effective in metastatic tumors, which is a real challenge facing current tumor therapies. Additionally, it confers long-lasting memory, which cannot by induce by other therapeutic approaches [1]. T cell is the major cell orchestrating the anti-tumor immune response. For a T cell to be activated and differentiated, it should receive activating signal not only from the T cell receptor but also from other co-stimulatory molecules [2]. On the other hand, to maintain a balanced immune system other molecule are involved in the inhibition of the activated T cell after the end of an immune response. Understanding these pathways can help in influencing the activity of T cell and thus provide other options for cancer immunotherapy [3].","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Novel approaches in cancer study","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31031/nacs.2019.03.000570","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Tumor immunotherapy exceeds radiotherapy and chemotherapy in the fact that it considered the most tumor-specific therapy; it is characteristically effective in metastatic tumors, which is a real challenge facing current tumor therapies. Additionally, it confers long-lasting memory, which cannot by induce by other therapeutic approaches [1]. T cell is the major cell orchestrating the anti-tumor immune response. For a T cell to be activated and differentiated, it should receive activating signal not only from the T cell receptor but also from other co-stimulatory molecules [2]. On the other hand, to maintain a balanced immune system other molecule are involved in the inhibition of the activated T cell after the end of an immune response. Understanding these pathways can help in influencing the activity of T cell and thus provide other options for cancer immunotherapy [3].